Physician profile
Benjamin H Epstein
NPI 1437263902
$5,119.65
in general payments reported to CMS, 2019-2025
36 companies · $755 in 2025
The $755 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.69 · 2020: $42.40 · 2021: $68.36 · 2022: $317 · 2023: $3,163 · 2024: $744 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,300 · Food and Beverage: $2,189 · Travel and Lodging: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,300.00 |
| Food and Beverage | $2,188.97 |
| Travel and Lodging | $174.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $2,474.03 | 2023 | Aristada, Aristada Initio |
| Pfizer INC. | $357.01 | 2022-2025 | |
| Novo Nordisk INC | $333.03 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $225.55 | 2022-2025 | |
| Exact Sciences Corporation | $179.91 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $147.82 | 2023-2025 | |
| Glaxosmithkline, LLC. | $135.55 | 2022-2024 | Shingrix, Arexvy |
| Lilly USA, LLC | $129.11 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Otsuka America Pharmaceutical, INC. | $127.04 | 2020-2023 | Rexulti, Jynarque |
| Astrazeneca Pharmaceuticals Lp | $120.44 | 2022-2024 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.07 | 2023-2025 | Ofev, Jardiance |
| Novartis Pharmaceuticals Corporation | $79.16 | 2023-2024 | |
| Abbott Laboratories | $77.64 | 2023-2025 | Freestyle Libre 3, Freestyle Libre |
| Esperion Therapeutics, INC. | $75.82 | 2021-2025 | Nexletol |
| Dynavax Technologies Corporation | $53.67 | 2023-2024 | Heplisav-B |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Epstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.